Alvotech Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenues: $106 million, a 20% decline year-over-year.

Product Revenues: $51 million, driven by biosimilars AVT02 (Humira) and AVT04 (Stelara).

Licensing Revenues: $55 million, impacted by milestone timing.

Adjusted EBITDA: $24 million (23% margin), up from $21 million (15% margin) in Q1 2025.

Gross Margin: 57%, a slight improvement year-over-year.

Cash Position: $64 million, with negative operating cash flow of $25 million due to working capital needs.

Guidance for 2026: Revenue target of $650 million to $700 million; adjusted EBITDA expected between $180 million and $220 million.

2Strategic Updates and Business Highlights

Focus on FDA resubmission and maintaining inspection readiness, with a routine GMP surveillance inspection ongoing at the Reykjavik facility.

Partnership with Fujifilm Biotechnologies to enhance U.S.-based manufacturing capacity, expected to support product supply starting in H2 2027.

Continued expansion of commercial business with launches of three biosimilars across Europe and other markets.

Strong demand trends for biosimilars, particularly AVT02, which has captured a 10% market share in the U.S.

3Forward Guidance and Outlook

Anticipated strong growth in 2027, driven by new product launches and a robust pipeline of 30 biosimilars.

Expected improvement in product revenues as normal operations resume post-facility improvements.

Long-term growth supported by submissions for biosimilars to Entyvio and high-dose Eylea in 2026.

4Bad News, Challenges, or Points of Concern

Production Slowdown: Ongoing facility improvements have impacted manufacturing throughput, contributing to reduced product revenues.

Market Dynamics: Competitive pressures in the biosimilar market, particularly with evolving market shares and pricing strategies.

Regulatory Risks: The need for successful FDA inspection outcomes and the potential for delays in product approvals.

Cash Flow: Negative operating cash flow and reliance on milestone revenues create financial strain.

5Notable Q&A Insights

Fujifilm Partnership: Seen as a strategic move to diversify manufacturing capacity, but specifics on future sales contributions remain unclear.

Market Share Dynamics: Growth in the U.S. biosimilar market is attributed to increased adoption and effective commercial execution, while European markets show stability with potential for growth.

Regulatory Timeline: The FDA inspection is ongoing, with expectations to resubmit BLAs by the end of Q2 2026, aiming for approvals by year-end.

German Market Reforms: Potential opportunities exist despite concerns over a shift to a tender market, with strong partnerships expected to mitigate risks. This summary encapsulates Alvotech's financial performance, strategic initiatives, and outlook while addressing challenges and insights from the Q&A session.